Please login to the form below

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

Incyte’s JAK inhibitor cream clears second eczema trial

The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for

Latest news

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).
AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

tofacitinib) and Eli Lilly’s Olumiant (baricitinib). ... The revised report also determined that Xeljanz had a comparable net health benefit to Humira, while there is no evidence to compare Olumiant to the older treatment.
Second TULIP trial resurrects AZ’s lupus drug anifrolumab

There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)
AbbVie scores FDA approval for arthritis treatment upadacitinib

The JAK inhibitor market competition has also become increasingly saturated and upadacitinib will be taking on Pfizer’s Xeljanz and Eli Lilly’s Olumiant when it comes to market.
Gilead and Galapagos close in on filing for Xeljanz rival

If approved, filgotinib would likely be the fourth JAK inhibitor for RA after Pfizer’s $1.8bn seller Xeljanz (tofacitinib), Eli Lilly’s Olumiant (baricitinib), and AbbVie’s upadacitinib which has ... In both studies there was a low incidence of

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account Manager: Salary TBC

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Account Manager (PR): Great Benefits

Senior External Communications Lead: £Competitive Salary

Account Director, Healthcare Communications: Salary TBC

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Director – UK Office: Excellent salary and benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Medical Writer: Salary TBC

Senior Medical Writer, MedComms Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Manager: £Competitive Salary

Account Director: £Competitive Salary

Account Director, Medical Education: Salary TBC

PMHub

Add my company

Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

The role of women in science and technology: Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances: China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program: Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....